Additional file 2 of Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide

Additional file 2 of Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide

Additional file 2. Tables S1-10. Table S1. List of primers used for ChIP-qPCR. Table S2. List of primers used for RT–qPCR. Table S3. Demographic and clinical characteristics of the 28 relapsed/refractory NKTL patients. Table S4. Patient characteristics at baseline. Table S5. List of GAIN and LOSS re...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Chen, Jinghong, Zuo, Zhixiang, Gao, Yan, Yao, Xiaosai, Guan, Peiyong, Wang, Yali, Li, Zhimei, Liu, Zhilong, Hong, Jing Han, Deng, Peng, Chan, Jason Yongsheng, Cheah, Daryl Ming Zhe, Lim, Jingquan, Chai, Kelila Xin Ye, Chia, Burton Kuan Hui, Pang, Jane Wan Lu, Koh, Joanna, Huang, Dachuan, He, Haixia, Sun, Yichen, Liu, Lizhen, Liu, Shini, Huang, Yuhua, Wang, Xiaoxiao, You, Hua, Saraf, Sahil Ajit, Grigoropoulos, Nicholas Francis, Li, Xiaoqiu, Bei, Jinxin, Kang, Tiebang, Lim, Soon Thye, Teh, Bin Tean, Huang, Huiqiang, Ong, Choon Kiat, Tan, Jing
Format: Dataset
Sprache:eng
Schlagworte:
Biochemistry
Biological Sciences not elsewhere classified
Biotechnology
Cancer
Chemical Sciences not elsewhere classified
FOS: Biological sciences
FOS: Health sciences
Genetics
Hematology
Infectious Diseases
Medicine
Pharmacology
Space Science
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Additional file 2. Tables S1-10. Table S1. List of primers used for ChIP-qPCR. Table S2. List of primers used for RT–qPCR. Table S3. Demographic and clinical characteristics of the 28 relapsed/refractory NKTL patients. Table S4. Patient characteristics at baseline. Table S5. List of GAIN and LOSS regions identified in both resistant and sensitive samples. Table S6. List of motifs in GAIN regions. Table S7. List of GAIN and LOSS regions overlapping with nearest genes identified in both resistant and sensitive samples. Table S8. List of differentially expressed genes overlapping with GAIN and LOSS regions in sensitive versus resistant samples. Table S9. Differentially expressed genes from JAK-STAT pathway in sensitive versus resistant samples. Table S10. Differentially expressed genes in HANK1 treated with DMSO, tofacitinib or ruxolitinib.
DOI:10.6084/m9.figshare.22598594